Background Endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) of primary varicose vein are thought to minimize postoperative morbidity and reduce work loss compared with the conventional surgical procedure. Aim of the Work to determine, whether endovenous ablation (radiofrequency and laser) have any advantages or disadvantages in comparison with conventional surgery, in the treatment of primary varicose vein. Patients and Methods this is a prospective randomized study. Thirty Patients presented at Vascular Outpatient Clinic for management of chronic venous insufficiency. All patients underwent clinical examination and duplex ultrasonography. Ten (10) patients were treated with ligation and stripping of the GSV or SSV. Ten (10) patients were treated with Radiofrequency ablation. Ten (10) patients were treated with endovenous laser ablation. The study was conducted at Ain Shams University Hospitals and Helwan University Hospitals. The study took place from September 2017 to June 2018. Results Compared with conventional surgery, endovenous ablation methods reduce postoperative discomfort and pain, with a lower complication rate after treatment for avoidance of a groin incision and dissection at the saphenofemoral confluence. Cosmetic demands are also better satisfied. However, risks of EVLA and RFA remain in terms of recanalization and neoreflux via junctional tributaries. Conclusion RFA and EVLA are minimally invasive procedures. Their potential early benefits, by avoiding groin dissection and GSV stripping, have been confirmed by the findings from this trial. Current evidence based on randomized trials consistently demonstrates significant early benefits after RFA and EVLA in suitable patients with varicose veins.
Background chronic liver disease and cirrhosis are important causes of morbidity and mortality in the world. Moreover, the burden of chronic liver disease is projected to increase due in part to the increasing prevalence of end-stage liver disease and HCC secondary to NAFLD and HCV. Aim of the Work in this study we will aim to clarify the importance of adequate venous drainage in right lobe grafts in living donor liver transplantation to determine its impact on the graft survival and avoidance of small for size graft syndrome as regard operative time, operative mortality rates (throughout the first month), normalization of liver functions and 6 month, 1 year survival rates of the patients. Patients and Methods our study population includes all the patients who performed right lobe living donor liver transplantation from January 2014 till June 2018 at the liver transplantation unit at Ain Shams Specialized University Hospital and will be classified in our study into 2 groups: First group Patients for whom we performed a single venous anastmosis including 42 cases. Second group Patients for whom we performed multiple venous anastmoses whether an additional single or double or triple anastmoses including 43 cases. Results our study was held as a retrospective cohort study to compare between the patients who received a single venous anastmosis as the first group (n = 42) and the patients who received multiple venous anastmosis as the second group (n = 43). Conclusion so here we can declare, according to our results, that the second group has better survival rates, less mortality rates, better graft survival, better course when daily follow up with full labs is done concerning platelets levels, ALT, direct bilirubin, INR and according to those results we highly recommend multiple hepatic venous anastmosis, if indicated, to acheive the best results in every single LDLT despite the longer cold and warm ischemic time.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.